Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M346Revenue (TTM) $M46.4Net Margin (%)-197.5Altman Z-Score-9.3
Enterprise Value $M311EPS (TTM) $-0.4Operating Margin %-182.5Piotroski F-Score4
P/E(ttm)--Beneish M-Score0.5Pre-tax Margin (%)-197.8Higher ROA y-yY
Price/Book10110-y EBITDA Growth Rate %-28.1Quick Ratio2.1Cash flow > EarningsY
Price/Sales7.45-y EBITDA Growth Rate %-24.0Current Ratio2.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-37.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-240.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M243ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with ARNA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARNAKen Fisher 2016-03-31 Sold Out $1.41 - $1.97
($1.61)
$ 1.42-12%Sold Out0
ARNAKen Fisher 2015-12-31 Add$1.7 - $2.4
($2.04)
$ 1.42-30%Add 0.91%11,100
ARNAKen Fisher 2013-12-31 Buy $4.08 - $6.66
($5.22)
$ 1.42-73%New holding11,000
ARNAMario Gabelli 2011-03-31 Sold Out $1.41 - $2.16
($1.7)
$ 1.42-16%Sold Out0
ARNAMario Gabelli 2010-12-31 Buy $1.27 - $2.38
($1.58)
$ 1.42-10%New holding13,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARNA is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ARNA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
White Christine AnnaDirector 2016-06-13Sell18,728$1.99-28.64view
WOODS RANDALL EDirector 2015-03-30Sell76,268$4.49-68.37view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-03-17Sell70,000$5-71.6view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-01-08Sell45,000$6.26-77.32view
SHANAHAN WILLIAM R JRSVP & Chief Medical Officer 2015-01-07Sell50,000$5.49-74.13view
LIEF JACKChairman, President and CEO 2014-07-01Sell223,525$5.85-75.73view
BELCHER DONALD DDirector 2014-06-27Sell2,473$5.85-75.73view
SPECTOR STEVEN WEVP, General Counsel & Sec 2014-05-12Sell45,000$7.05-79.86view
BELCHER DONALD DDirector 2014-05-06Sell4,176$7-79.71view
HIXSON HARRY F JRDirector 2014-04-22Sell36,900$6.31-77.5view

Quarterly/Annual Reports about ARNA:

News about ARNA:

Articles On GuruFocus.com
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
(ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results Nov 16 2013 
WEEKLY CFO SELLS HIGHLIGHT: ZNGA, ARNA, JACK, TUMI, PANW Apr 07 2013 
WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC Oct 07 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
Arena Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
Arena Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
Puma (PBYI) Expands Study Cohort for Lead Candidate PB272 Jan 09 2017
Vertex Pharma Issues Disappointing 2017 Orkambi Outlook Jan 09 2017
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 06 2017
Arena Pharmaceuticals Dumps Belviq Weight Loss Drug Jan 06 2017
Genocea Stock Up on Positive Genital Herpes Infections Data Jan 06 2017
Biogen Licenses Amunix's XTEN Technology for Factor IX Drug Jan 06 2017
Arena, Eisai Modify Marketing & Supply Agreement for Belviq Jan 05 2017
Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III Jan 05 2017
Allergan (AGN) Liletta sNDA Accepted for Review in the U.S. Jan 05 2017
Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US :... Jan 05 2017
Eisai Acquires All Global Development and Marketing Rights for Chronic Weight Management Treatment... Jan 04 2017
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jan 04 2017
Arena Pharmaceuticals and Eisai Amend Marketing and Supply Agreement for BELVIQ Globally Jan 04 2017
Clovis Declares Pricing of Upsized Offering of Common Stock Jan 04 2017
Allergan Natrelle Inspira Breast Implants Approved in the U.S. Jan 04 2017
Arena Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ARNA) : December 27, 2016 Dec 27 2016
Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US :... Dec 26 2016
Eisai and Arena Pharmaceuticals Announce Regulatory Approval of BELVIQ® (lorcaserin HCl) in Brazil Dec 19 2016
ETFs with exposure to Arena Pharmaceuticals, Inc. : December 19, 2016 Dec 19 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)